Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy

NCT ID: NCT01300273

Last Updated: 2011-09-08

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE4
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-02-28
• Study Completion Date: 2012-07-31

Brief Summary

The investigators hypothesize that, LPD supplemented with ketoanalogs will reduce urine podocyte loss and lower the angiotensinogen level in the urine.

Detailed Description

Diabetic nephropathy is one of the most important causes of end stage renal disease in the world. Recently In a multicenter, randomized clinical trial performed in China, which aimed to evaluate the efficacy and safety of compound α-keto acid tablet in combination with low protein diet (LPD+KA) in delaying the progress of type 2 diabetic nephropathy(T2DN). In that study it was found that LPD+KA was associated with amelioration of proteinuria, better reduction in the loss of kidney function compared with LPD alone meanwhile nutrition status remained well in both group(Role of Ketoanalogs in diabetic nephropathy-China study, to be submitted for publication). However, in that study the mechanisms underlined these effects were not been elucidated This research proposal is a part of the continuation of that study. Restriction of Protein intake, strictly control blood pressure, particularly using renin-angiotensin system (RAS) blockade have been shown to ameliorate proteinuria and progression of CKD. Podocyte damage has been know to play critical role for proteinuria and renal function loss A recent study showed that the mRNA expression of podocyte markers in urinary sediment is increased in patients with T2DN, and this effect can be inhibited by ACE inhibitor and ARB, which indicates the important role of local renal RAS to involve in the damage. Urinary angiotensinogen level is a good marker of the situation of renal RAS. Consequently the investigators are proposing to study the effect of LPD+KA on podocyte as well as on local RAS in the kidney.

Conditions

Type 2 Diabetic Nephropathy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Ketosteril

Group Type: EXPERIMENTAL

Compound α-Ketoacid Tablet

Intervention Type: DIETARY_SUPPLEMENT

30 patients will be treated with a LPD containing 0.6g protein/kg BW per day and 120-125 kJ/kg BW per day and supplemented with keto-amino acids (Ketosteril®, Fresenius Kabi) at a dosage of 100 mg/kg BW per day.

Interventions

Compound α-Ketoacid Tablet

30 patients will be treated with a LPD containing 0.6g protein/kg BW per day and 120-125 kJ/kg BW per day and supplemented with keto-amino acids (Ketosteril®, Fresenius Kabi) at a dosage of 100 mg/kg BW per day.

Intervention Type: DIETARY_SUPPLEMENT

Other Intervention Names

Ketosteril; Ketoanalogs

Eligibility Criteria

Inclusion Criteria

• diagnosed with type 2 diabetes
• age range is 18 - 80 years old
• no gender restrictions
• use oral hypoglycemic agents (limited to repaglinide, α-glucosidase inhibitor and chloroquine ketone) and/or insulin to control blood sugar
• fasting blood sugar is not higher than 10mmol/l, glycated hemoglobin is not higher than 8.5%
• using RAS system blockers (ACEI or ARB) for at least 4 weeks and blood pressure is no higher than 160/90mmHg. Once enrolled in the group, the dose should not be changed, unless there is contraindication
• has not yet started dialysis, GFR based on simplified MDRD formula is between (15-60) ml/min/1.73m2
• serum albumin is not less than 25g/l and appearing dominant proteinuria (urinary albumin excretion rate > 300mg/24h)
• understanding and willing to participate in the trial and signed informed consent

Exclusion Criteria

• compliance is poor
• GFR < 15ml/min/1.73m2
• repeated hypercalcemia, hyperkalemia
• ketoacidosis occurred in recent 6 months
• chronic heart failure, above NYHA 3 grade
• combined with other serious diseases in 3 months
• obvious symptoms and signs of liver disease. Alanine or aspartate aminotransferase 2 times higher than normal
• severe edema, or up to the level of nephrotic syndrome or that there is serous cavity effusion
• urinary tract infections or other urinary tract diseases
• drug abusers
• diagnosed of malignancy
• receiving long-term systemic steroid therapy
• women pregnancy or Intended pregnancy and breastfeeding
• took part in other clinical drug studies 30 days before the trial

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Huashan Hospital

OTHER

Sponsor Role: collaborator

Shanghai East Hospital

OTHER

Sponsor Role: collaborator

Shanghai 6th People's Hospital

OTHER

Sponsor Role: collaborator

Shanghai Jiao Tong University School of Medicine

OTHER

Sponsor Role: lead

Responsible Party

Weijie Yuan

Chief physician, Director of Department of Nephrology

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Weijie Yuan, Professor

Role: PRINCIPAL_INVESTIGATOR

Department of Nephrology, First People's Hospital, Shanghai Jiao Tong University

Locations

Department of Nephrology,Shanghai Jiaotong University Affiliated First People's Hospital

Shanghai, Shanghai Municipality, China

Countries

China

References

Kasiske BL, Lakatua JD, Ma JZ, Louis TA. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis. 1998 Jun;31(6):954-61. doi: 10.1053/ajkd.1998.v31.pm9631839.

Reference Type: BACKGROUND

PMID: 9631839 (View on PubMed)

Mahmood J, Khan F, Okada S, Kumagai N, Morioka T, Oite T. Local delivery of angiotensin receptor blocker into the kidney ameliorates progression of experimental glomerulonephritis. Kidney Int. 2006 Nov;70(9):1591-8. doi: 10.1038/sj.ki.5001872. Epub 2006 Sep 20.

Reference Type: BACKGROUND

PMID: 16985512 (View on PubMed)

Wang G, Lai FM, Lai KB, Chow KM, Li KT, Szeto CC. Messenger RNA expression of podocyte-associated molecules in the urinary sediment of patients with diabetic nephropathy. Nephron Clin Pract. 2007;106(4):c169-79. doi: 10.1159/000104428. Epub 2007 Jun 26.

Reference Type: BACKGROUND

PMID: 17596726 (View on PubMed)

Wang G, Lai FM, Lai KB, Chow KM, Kwan BC, Li PK, Szeto CC. Urinary messenger RNA expression of podocyte-associated molecules in patients with diabetic nephropathy treated by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker. Eur J Endocrinol. 2008 Mar;158(3):317-22. doi: 10.1530/EJE-07-0708.

Reference Type: BACKGROUND

PMID: 18299464 (View on PubMed)

Yamamoto T, Nakagawa T, Suzuki H, Ohashi N, Fukasawa H, Fujigaki Y, Kato A, Nakamura Y, Suzuki F, Hishida A. Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease. J Am Soc Nephrol. 2007 May;18(5):1558-65. doi: 10.1681/ASN.2006060554. Epub 2007 Apr 4.

Reference Type: BACKGROUND

PMID: 17409316 (View on PubMed)

Adey D, Kumar R, McCarthy JT, Nair KS. Reduced synthesis of muscle proteins in chronic renal failure. Am J Physiol Endocrinol Metab. 2000 Feb;278(2):E219-25. doi: 10.1152/ajpendo.2000.278.2.E219.

Reference Type: BACKGROUND

PMID: 10662705 (View on PubMed)

Sato N, Komatsu K, Kurumatani H. Late onset of diabetic nephropathy in spontaneously diabetic GK rats. Am J Nephrol. 2003 Sep-Oct;23(5):334-42. doi: 10.1159/000072915. Epub 2003 Aug 13.

Reference Type: BACKGROUND

PMID: 12920324 (View on PubMed)

Verity MA. Infantile Pompe's disease, lipid storage, and partial carnitine deficiency. Muscle Nerve. 1991 May;14(5):435-40. doi: 10.1002/mus.880140509.

Reference Type: BACKGROUND

PMID: 1870635 (View on PubMed)

Other Identifiers

KETO-011-IP4

Identifier Type: -

Identifier Source: org_study_id